## Investigation of Choice for ACE Inhibitor Teratogenicity ### Clinical Context ACE inhibitors are contraindicated in pregnancy, particularly in the second and third trimesters, due to risk of fetal renal dysgenesis, oligohydramnios, and intrauterine growth restriction (IUGR). The patient is at 16 weeks—within the window of concern. ### Why High-Resolution Ultrasound? **Key Point:** Renal structural abnormalities and amniotic fluid volume are best assessed by real-time ultrasound imaging. This is the gold standard for detecting fetal renal dysgenesis, bilateral renal agenesis, or severe oligohydramnios—the hallmark manifestations of ACE inhibitor exposure. **High-Yield:** Ultrasound findings in ACE inhibitor fetopathy include: - Bilateral renal hypoplasia or agenesis - Severe oligohydramnios (amniotic fluid index <5 cm) - IUGR - Fetal hypotension and renal hypoperfusion signs These are visible and measurable on ultrasound from 16–20 weeks onward. ### Why Not the Other Investigations? | Investigation | Why Not Appropriate | |---|---| | **AFP & unconjugated estriol** | These are screening markers for chromosomal abnormalities (Down syndrome, Edwards syndrome), not for drug-induced renal dysgenesis. | | **Fetal echocardiography** | While cardiac effects can occur, renal structural damage is the primary concern and is not assessed by echo. | | **Amniocentesis & karyotyping** | Karyotyping rules out chromosomal causes, not teratogenic drug effects. It carries procedural risk and is not indicated for suspected drug teratogenicity. | **Clinical Pearl:** If oligohydramnios is severe and confirmed, delivery planning and neonatal renal function assessment become urgent—ACE inhibitor exposure in the second/third trimester often necessitates early delivery to prevent fetal demise.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.